A new study has found that B-cell depletion therapy (which destroys autoimmune disease producing B cells) using rituximab has the potential to treat skin lesions in people with severe active cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE). CLE is one of four different types of lupus, and is limited to the skin and can cause many types of rashes and lesions. This study revealed that 61 percent of participants had improved skin lesions one year after treatment, and more than half saw a complete healing of their lesions. Read more about the four types of lupus and in detail about CLE.
Lupus Foundation of America, Midwest
Joan Pendleton
312-459-6271
Pendleton@lupus.org
There are multiple chapters near you. Select your preferred chapter.
Supporting lupus patients and advocates in Arizona.
Serving the District of Columbia, Maryland, and Northern Virginia.
Serving Kansas, Missouri, and Central & Southern Illinois
Serving north, central and west Texas, including Dallas/Fort Worth, San Antonio, Austin, El Paso, Lubbock, and surrounding areas
Serving Northern Illinois, Indiana, Iowa, Michigan, and Minnesota
Serving Connecticut, Massachusetts, Maine, New Hampshire, northern and central New Jersey, New York, Rhode Island, and Vermont
Serving Pennsylvania, Delaware and Southern New Jersey
Serving Houston, Beaumont, Corpus Christi, Harlingen and surrounding areas in Texas
There are multiple walks near you.
This website uses cookies to ensure you get the best experience. Learn more